ArticleLancet (London, England)2016

Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial.

Jean Bennett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.